Genmab A/S
HealthcareNASDAQ:GMAB · NASDAQ Global Select
-$0.16 today
Vol 1.11M · Avg 1.80M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
16.5%
avg 18.9%
ROIC
8.5%
avg 16.5%
ROA
7.5%
avg 16.4%
Analysis
ROE is currently the strongest return metric at 16.5% versus its period average of 18.9%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jan van de Winkel | Co-Founder, President & Chief Executive Officer | $3.30M | — | 65 | — | — |
Rayne Waller | Executive Vice President & Chief Technical Operations Officer | $1.80M | — | 58 | — | — |
Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer | $1.70M | — | 55 | — | — |
Judith V. Klimovsky | Executive Vice President & Chief Development Officer | $1.30M | — | 68 | — | — |
Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer & Head of Experimental Medicines | $1.30M | — | 53 | — | — |
Anthony Pagano | Executive Vice President & Chief Financial Officer | $1.10M | — | 48 | — | — |
Martine J. van Vugt | Executive Vice President & Chief Strategy Officer | $900,000.00 | — | 55 | — | — |
Christopher Cozic | Executive Vice President & Chief People Officer | $800,000.00 | — | 47 | — | — |
Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director | $300,000.00 | — | 51 | — | — |
Mijke Zachariasse | Vice President, Head of Antibody Research Materials & Director | $300,000.00 | — | 53 | — | — |
Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director | $100,000.00 | — | 51 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +5.2% (15yr)14 analysts |
| Revenue | N/A | N/A | +32.7% | +12.3% (15yr)9 analysts |
| Net Income | N/A | N/A | N/A | +5.4% (15yr)9 analysts |
| EBIT | N/A | N/A | N/A | +9.0% (15yr)9 analysts |
Analysis
Recent growth has been strongest in Revenue at +32.7% over three years. Forward estimates point to Revenue at +12.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Illumina, Inc.
NASDAQ:ILMN
$24.35B
Royalty Pharma plc
NASDAQ:RPRX
$23.60B
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Incyte Corporation
NASDAQ:INCY
$21.68B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.61B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
Who manages GMAB?
Genmab A/S (GMAB) lists 11 active executives. The top listed executive is Judith V. Klimovsky, Executive Vice President & Chief Development Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.